Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OSP:rTTHc cholera conjugate vaccine without aluminum + Euvichol-Plus
- Development stage
- Unknown
- Lead developer
- International Vaccine Institute
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Oral
01
Overview
OSP:rTTHc cholera conjugate vaccine without aluminum + Euvichol-Plus is a combination vaccine regimen being evaluated for the prevention of cholera. It consists of an injectable conjugate vaccine (CCV) and a bivalent inactivated oral cholera vaccine (OCV). The CCV component, developed by the International Vaccine Institute (IVI) in partnership with EuBiologics and Massachusetts General Hospital, features the O-specific polysaccharide (OSP) from Vibrio cholerae O1 Inaba El Tor strain conjugated to a recombinant tetanus toxoid heavy chain fragment (rTTHc). This specific formulation excludes aluminum adjuvants. Euvichol-Plus is an established oral vaccine containing inactivated V. cholerae O1 and O139. The combination aims to provide both systemic and mucosal immunity to enhance protection in endemic regions.
- Other names
- CCV without aluminum + Euvichol-PlusOSP:rTTHc CCV 25 ㎍ without Aluminum phosphate + Euvichol-Plus
02
Targets
Vibrio cholerae O1 lipopolysaccharide O-antigen
Beyond the preview
Go deeper on OSP:rTTHc cholera conjugate vaccine without aluminum + Euvichol-Plus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OSP:rTTHc cholera conjugate vaccine without aluminum + Euvichol-Plus.